Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A

Ratings ESG MSCI

Ratings Moderna, Inc.: Strengths and Weaknesses

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Moderna, Inc.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Moderna, Inc.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Rating Financials

Moderna, Inc. SectorUnited States
Fundamentals -
Growth
Revenue growth
EPS growth
FCF growth
Profitability-
EBITDA Margin-
EBIT Margin-
Net Margin-
Capital Efficiency
ROA
ROCE
ROE
Financial Health-
Gearing
Leverage-
Capital Intensity-
Balance sheet growth
Long Term balance sheet growth
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

Moderna, Inc. SectorUnited States
Global Valuation -
Enterprise value-
EV/Revenue
EV/EBITDA-
EV/FCF-
Equity Valuation-
P/E-
PBR
Dividend Yield-
EV/EBIT-
CAPEX/Revenue
More ratings

Rating Consensus

Moderna, Inc. SectorUnited States
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Moderna, Inc. SectorUnited States
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Moderna, Inc. SectorUnited States
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
11.69B -
A
- -
77.22B
A
57.5B
AA
55.88B
BBB
53.2B
AA
25.78B
AA
19.37B
AA
18B
AAA
15.88B
CCC
14.36B -
BB
- -
Average 34.89B
A
Weighted average by Cap.
A
See all sector ratings